Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

by Team Lumida
June 5, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Apparel returns are surging as GLP-1 users rapidly lose weight, with one online retailer reporting a 50% increase in returns in the past year — a direct hit to gross margins that can cost a $1 billion retailer $20 million or more.
  • The share of apparel exchanges where shoppers sized down hit a record 14.6% in 2025, up for three consecutive years, according to a review of 38 retailers by returns manager Narvar.
  • Returns for medium, large, and extra-large items are rising the fastest, according to Impact Analytics, as GLP-1 users cycle through multiple sizes while their bodies change — sometimes dropping a full size every few weeks at peak weight loss.
  • Retailers are responding with higher restocking fees (one doubling its fee to 20%), stricter size chart guidance, and smaller-size inventory increases — but the structural problem is growing as GLP-1s become cheaper and more accessible via pill form.

What Happened?

America’s apparel retailers are grappling with a new source of margin pressure: the mass adoption of GLP-1 weight-loss medications. At peak weight loss, users of drugs like Zepbound can drop a full clothing size every month, and they’re responding by ordering multiple sizes simultaneously and returning what doesn’t fit. Online budget suit retailer FlexSuits has seen a 50% increase in returns over the past year, with founder Farnam Elyasof flagging multi-size orders as a “red flag.” The problem is particularly acute in mid-range sizes: returns for medium, large, and XL items are rising fastest, per Impact Analytics, as GLP-1 users shop while uncertain about where their bodies will land.

Why It Matters?

Returns are among the most destructive forces in retail economics. Shipping, labor, and warehousing costs compound quickly, and out-of-season items returned after their selling window must be marked down. For a $1 billion apparel company with a typical 20% return rate, a 5-to-10 percentage point increase in returns can wipe $20 million off gross margins. The GLP-1 return wave isn’t a blip — it’s structural. An estimated 60% of returns at one women’s brand now cite “item too big” or weight loss as the reason, up from 30-40% a year ago. As GLP-1s become cheaper and expand to a pill form, the user base — and the return rate — will likely grow further. Retailers from Levi Strauss to Costco and Walmart are all actively studying the shift.

What’s Next?

Retailers are adapting on multiple fronts: higher restocking fees (one retailer doubled its fee to 20% of purchase price), more detailed size guidance, and shifts in inventory mix toward smaller sizes. Some are applying stricter return policies to reduce “bracket buying” — ordering multiple sizes with intent to return. But the fundamental challenge remains: a consumer base in active physical transition is inherently difficult to serve with fixed-size merchandise. As GLP-1 adoption widens, the retailers best positioned will likely be those with strong loyalty data, flexible return economics, or direct-to-consumer models where they can engage customers through their weight-loss journey rather than just at the point of purchase.

Source: The Wall Street Journal

Previous Post

Trump Officials Are Feuding Over Whether a Policy Loophole Let China Buy Nvidia’s Most Advanced AI Chips

Next Post

Apple’s Bet on AI Supremacy Starts With Finally Fixing Siri — Using Google’s Technology

Recommended For You

Novo Nordisk’s $10 Billion Cardiovascular Bet Fails — Ziltivekimab Misses Heart Attack and Stroke Endpoint, Stock Drops 10.5%

by Team Lumida
5 days ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk's experimental drug ziltivekimab — a monthly IL-6 inhibitor injection targeting cardiovascular disease, chronic kidney disease, and inflammation in a market Jefferies estimates at $10B+ annually —...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
7 days ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more

80% of People Are Deficient in Essential Vitamins — Here Are the 10 You Actually Need and Where to Get Them

by Team Lumida
1 week ago
oranges, peas, and limes on a wooden table

Most people are not getting enough of the 13 essential vitamins their bodies require — here is a practical guide to the most critical nutrients, what they do,...

Read more

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

by Team Lumida
2 weeks ago
a close up of a human skull on a black background

Whoop and surgical software company Kinomatic have launched a 12-week pilot program called Restore across three California orthopedic clinics to test whether continuous biometric monitoring — heart rate...

Read more

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
3 weeks ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
3 weeks ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
3 weeks ago
doctor holding red stethoscope

The share of health information exchanges reporting instances of information blocking fell from over 90% in 2019 to 71% in 2025, according to new ONC data — but...

Read more

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
1 month ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more

FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

by Team Lumida
1 month ago
FDA Reverses Rejection of Regenxbio Gene Therapy for Fatal Rare Disease

The FDA agreed to reverse its rejection of Regenxbio's Navsunli gene therapy for Hunter syndrome — the third rare-disease drug reversal under new FDA leadership, marking a retreat...

Read more
Next Post
Apple Store shop front

Apple's Bet on AI Supremacy Starts With Finally Fixing Siri — Using Google's Technology

Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic Calls for a Global Pause in Frontier AI Development, Warning of 'Recursive Self-Improvement' Risk

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a cell phone sitting on top of a laptop computer

U.S. Antitrust Agencies Support Musk’s Challenge to OpenAI-Microsoft Board Overlaps

January 11, 2025
Alphabet $GOOGL Q2 2024 Results

Alphabet’s $200 Billion Capex Forecast Spooks Investors — Stock Falls 4% After-Hours Despite Red-Hot Cloud Revenue

July 23, 2026
Berkshire Dumps Most of Amazon, Adds New York Times in Late-Stage Portfolio Shift

Berkshire Dumps Most of Amazon, Adds New York Times in Late-Stage Portfolio Shift

February 18, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018